Hematological Malignancies
Conditions
Brief summary
Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies.
Detailed description
Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies(including B-cell Acute lymphoblastic Leukemia、B-cell Chronic Lymphocytic Leukemia、Non-Hodgkin's lymphoma) and Determine the Best Dosage.
Interventions
BIOLOGICALIM19 CAR-T
All patients will be treated with fludarabine and cyclophosphamide for 3 days. Two days later, Cells Expressing an Anti-CD19 Chimeric Antigen Receptor will be infused.
DRUGFludarabine
Two days before cell infusion,all patients will be treated with fludarabine for 3 days
DRUGCyclophosphamide
Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days
Sponsors
Beijing Immunochina Medical Science & Technology Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with CD19 positive relapsed or refractory B-cell malignancies, including B-cell Acute Lymphocytic Leukemia(ALL)、B-cell Chronic Lymphocytic Leukemia(CLL)、Non-Hodgkin's lymphoma(NHL). 1)Patients with ALL: * Previously treated with at least two courses of chemotherapy Ⅱ The interval of the last chemotherapy and disease progression is less than one year. Ⅲ Not suitable for allogeneic stem cell transplantation. 2)Patients with CLL: * Previously treated with at least two courses of chemotherapy Ⅱ The interval of the last chemotherapy and disease progression is less than two years. Ⅲ Not suitable for allogeneic stem cell transplantation conditions or due to conditions to abandon allogeneic stem cell transplantation. 3\) Patients with DLBCL or FL、PMBCL: * Patients who relapsed or were refractory after at least two previous treatments. Ⅱ Patients who relapsed after transplantation. 4)Patients who have relapsed or have refractory mantle cell lymphoma after at least one treatment. 2.Measurable disease,including minimal residual disease. 3.Gender is not limited, to be aged 4 to 75 years 4.Expected survival \>3 months. 5.Eastern Cooperative Oncology Group(ECOG) score 0-2. 6.Women of childbearing potential must have a blood pregnancy test taken and proven negative prior to the treatment. All patients agree to use reliable methods of contraception during the trial period and until follow-up for the last time. 7.Absence of symptoms of central nervous system(CNS) leukemia.
Exclusion criteria
1. Patients who have been treated with chemotherapy or radiotherapy within 2 weeks before blood collection. 2. Patients have GVHD, which needs treatment with immunosuppressive agents,or patients with autoimmune diseases. 3. Patient who have been treated with systemic steroid medication within two weeks of blood collection（Except for the recent or current use of inhaled steroids）. 4. Patient who have been treated with stimulation of bone marrow hematopoietic cells generated drugs(Such as Recombinant Human Granulocyte Colony-stimulating Factor Injection) within 2 weeks before the blood collection period to use . 5. The number of T cells in peripheral blood is lower than 2×10\^8/L. 6. Previously treatment with any gene therapy products. 7. History of epilepsy or other CNS disease. 8. New York Heart Association(NYHA) grade≥Ⅲ. 9. Creatinine\> 1.5×normal value，Alanine transaminase(ALT) /Aspartate aminotransferase(AST)\>3×normal value，Bilirubin \>2×normal value. 10. Degree of myeloproliferation： Ⅳ-V 11. Active hepatitis B , hepatitis C or HIV infection and cytomegalovirus infection ,Epstein-Barr virus infection or any other uncontrolled active infection. 12. Pregnancy or breast-feeding women. 13. Any uncontrolled medical disorders that the researchers considered are not suitable to participate the clinical trial. 14. Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of study related adverse events | 2 years | defined as \>= Grade 3 signs/symptoms,laboratory toxicities,and clinical events that are possibly,likely,or definitely related to study treatment Adverse events assessed according to NCI-CTCAE v4.0 criteria 2. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate | 2 years | 2\. Overall response rate An objective response is defined as: (1) a morphologic complete response (CR) or (2) a complete response with incomplete recovery of counts (CRi) (based on NCCN guidelines (National Comprehensive Cancer Network (NCCN), 2014) or (3) a negative minimal residual disease assessed by flow cytometry |
Countries
China
Contacts
Primary ContactXin-an Lu, Dr
Outcome results
None listed